BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 25994910)

  • 1. [The prospects for children with acute lymphoblastic leukemia of being cured has increased in the Czech Republic in the 21st century to 90% - outcome of the ALL-IC BFM 2002 trial].
    Zdráhalová K; Štěrba J; Domanský J; Blažek B; Ptoszková H; Mihál V; Novák Z; Hak J; Procházková D; Černá Z; Timr P; Jabali Y; Sedláček P; Smíšek P; Zemanová Z; Jarošová M; Houdková A; Mejstříková E; Hrušák O; Zuna J; Janotová I; Trka J; Starý J
    Cas Lek Cesk; 2015; 154(2):79-89. PubMed ID: 25994910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica.
    Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi A; Miniero R; Di Tullio MT; Lo Nigro L; Pession A; Rondelli R; Messina C; Santoro N; Mori PG; De Rossi G; Tamaro P; Silvestri D; Biondi A; Basso G; Masera G
    Haematologica; 1998 Sep; 83(9):791-9. PubMed ID: 9825576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
    Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
    Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica.
    Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi AM; Messina C; Mori PG; Miniero R; Colella R; Basso G
    J Clin Oncol; 1995 Oct; 13(10):2497-502. PubMed ID: 7595699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic features: randomized controlled trial from the Children's Cancer Group.
    Steinherz PG; Gaynon PS; Breneman JC; Cherlow JM; Grossman NJ; Kersey JH; Johnstone HS; Sather HN; Trigg ME; Uckun FM; Bleyer WA
    Cancer; 1998 Feb; 82(3):600-12. PubMed ID: 9452280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Favorable outcome for children and adolescents with T-cell lymphoblastic lymphoma with an intensive ALL-type therapy without local radiotherapy.
    Grenzebach J; Schrappe M; Ludwig WD; Parwaresch R; Zimmermann M; Gadner H; Riehm H; Reiter A;
    Ann Hematol; 2001; 80 Suppl 3():B73-6. PubMed ID: 11757713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol II.
    Aricò M; Valsecchi MG; Conter V; Rizzari C; Pession A; Messina C; Barisone E; Poggi V; De Rossi G; Locatelli F; Micalizzi MC; Basso G; Masera G
    Blood; 2002 Jul; 100(2):420-6. PubMed ID: 12091331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group.
    Nachman J; Sather HN; Gaynon PS; Lukens JN; Wolff L; Trigg ME
    J Clin Oncol; 1997 Jun; 15(6):2222-30. PubMed ID: 9196134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment results with ALL-BFM-95 protocol in children with acute lymphoblastic leukemia in Hungary].
    Müller J; Kovács G; Jakab Z; Rényi I; Galántai I; Békési A; Kiss C; Nagy K; Kajtár P; Bartyik K; Masát P; Magyarosy E
    Orv Hetil; 2005 Jan; 146(2):75-80. PubMed ID: 15724956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92.
    Schlieben S; Borkhardt A; Reinisch I; Ritterbach J; Janssen JW; Ratei R; Schrappe M; Repp R; Zimmermann M; Kabisch H; Janka-Schaub G; Bartram CR; Ludwig WD; Riehm H; Lampert F; Harbott J
    Leukemia; 1996 Jun; 10(6):957-63. PubMed ID: 8667652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute lymphoblastic leukemia in children: nonrandomized comparison of conventional vs. intensive chemotherapy at the National Cancer Institute of Colombia.
    Buendia MT; Terselich G; Lozano JM; Viscaino MP
    Med Pediatr Oncol; 1997 Feb; 28(2):108-16. PubMed ID: 8986146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Improved results in children with acute lymphoblastic leukemia treated with the ALL-BFM 90 protocol in the Czech Republic].
    Starý J; Gajdos P; Blazek B; Ptoszková H; Mihál V; Pospísilová D; Hrstková H; Dembická D; Kopecná L; Slavík Z; Hak J; Procházková D; Zahálka F; Cerná Z; Jabali Y; Timr P; Vávra V; Mydlil J; Hrusák O; Trka J
    Cas Lek Cesk; 2003; 142(7):404-9. PubMed ID: 14515443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of IKZF1 deletions in association with vincristine-dexamethasone pulses during maintenance treatment of childhood acute lymphoblastic leukemia on trial ALL-BFM 95.
    Hinze L; Möricke A; Zimmermann M; Junk S; Cario G; Dagdan E; Kratz CP; Conter V; Schrappe M; Stanulla M
    Leukemia; 2017 Aug; 31(8):1840-1842. PubMed ID: 28529312
    [No Abstract]   [Full Text] [Related]  

  • 14. Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM- and CoALL-protocols: results of the German Cooperative Study.
    Dopfer R; Henze G; Bender-Götze C; Ebell W; Ehninger G; Friedrich W; Gadner H; Klingebiel T; Peters C; Riehm H
    Blood; 1991 Nov; 78(10):2780-4. PubMed ID: 1824271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Experiences with modified BFM protocols in the treatment of children with acute lymphoblastic leukemia (ALL) in East Germany 1981-1991].
    Zintl F; Malke H; Reimann M; Hermann J; Domula M; Dörffel W; Eggers G; Exadaktylos P; Hilgenfeld E; Kotte W
    Klin Padiatr; 1992; 204(4):221-9. PubMed ID: 1518257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High survival rate in childhood non-Hodgkin lymphoma without CNS involvement: results of BFM 95 study in Kuwait.
    Mottl H; Bajciova V; Nemec J; Al Shemmari S; Al Awadi S
    Pediatr Hematol Oncol; 2003 Mar; 20(2):103-10. PubMed ID: 12554521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Acute lymphoblastic leukemia in children with initial leucocytosis above 50,000/mm3: summary of treatment results of Polish Pediatric Leukemia/Lymphoma Study Group].
    Skoczeń S; Balwierz W; Moryl-Bujakowska A; Pawińska K; Luszczyńska A; Balcerska A; Płoszyńska A; Chybicka A; Dobaczewski G; Juszczak K; Wachowiak J; Derwich K; Kowalczyk J; Wiśniewska-Slusarz H; Matysiak M; Krauze A; Pawelec K; Sońta-Jakimczyk D; Tomaszewska R; Wysocki M; Styczyńskii J; Swiatkiewicz V;
    Przegl Lek; 2006; 63(1):11-4. PubMed ID: 16892892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
    Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J;
    J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia.
    Lauten M; Möricke A; Beier R; Zimmermann M; Stanulla M; Meissner B; Odenwald E; Attarbaschi A; Niemeyer C; Niggli F; Riehm H; Schrappe M
    Haematologica; 2012 Jul; 97(7):1048-56. PubMed ID: 22271901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The efficacy of BFM-90 program in the treatment of acute lymphoblastic leukemia in children in the studies of Polish pediatric leukemia/lymphoma group].
    Chybicka A; Bogusławska-Jaworska J; Gorczyńska E; Juszczak K; Armata J; Balcerska A; Balwierz W; Bubała H; Filiks-Litwin B; Kołecki P; Kowalczyk J; Lukowska K; Matysiak M; Rokicka-Milewska R; Rola-Kurc E; Stencel D; Sońta-Jakimczyk D; Strojny W; Wachowiak J; Wieczorek M; Wysocki M; Zelenay E
    Wiad Lek; 1998; 51 Suppl 4():25-32. PubMed ID: 10731940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.